CD274 and glioblastoma: Further, the oHSV-D11mt sensitized tumors to the treatment of ICB (anti-PD-L1 therapy) and improved the antitumor efficacy of either oHSV-D11mt or anti-PD-L1 monotherapy, extending the overall survival in GBM and BCBM tumor-bearing mice.